Dulaglutide Structural Integrity: Fc-Fusion Chain Verification Standards

 

Dulaglutide (Trulicity®) is a once-weekly GLP-1 receptor agonist engineered as an Fc-fusion protein, in which a modified GLP-1 analogue is covalently linked to a human IgG4 Fc domain via a peptide linker. 

The structural integrity of this molecule—particularly the fidelity of the Fc-fusion chain, disulphide connectivity, and post-translational modifications—is directly tied to its pharmacokinetic profile, receptor binding, and clinical safety. Verification standards for dulaglutide require a multi-attribute analytical framework combining intact mass analysis, peptide mapping, and potency assays to confirm that the fusion architecture maintains its intended conformation and function.

Molecular Architecture of Dulaglutide

Dulaglutide is a homodimer composed of two identical, disulphide-linked chains. Each chain contains three distinct structural domains: an N-terminal GLP-1 analogue sequence, a peptide linker, and a modified human IgG4 Fc fragment.

The GLP-1 analogue portion consists of the first 31 amino acids, corresponding to residues 3–37 of native human GLP-1, with three engineered substitutions: Ala8Gly, Gly22Glu, and Arg36Gly (relative to GLP-1 numbering). These modifications serve dual purposes: the Ala8Gly substitution confers resistance to dipeptidyl peptidase-4 (DPP-4) cleavage, extending the peptide’s circulating half-life, while the additional changes reduce potential immunogenicity.

A 16-amino acid glycine-serine linker (GGGGGGGSGGGGSG) connects the GLP-1 analogue to the Fc domain. This linker provides conformational flexibility, allowing the GLP-1 moieties to engage the GLP-1 receptor while the Fc domain performs its carrier and half-life-extending functions.

The Fc portion comprises 228 amino acids derived from a synthetic human IgG4 heavy chain constant region. The IgG4 backbone was selected and subsequently engineered to minimise Fc receptor binding and eliminate half-antibody formation, thereby enhancing structural homogeneity. The two chains assemble into a homodimer through inter-monomer disulphide bonds between Cys55 and Cys58 of each chain, with additional intra-chain disulphide bridges at positions 90–150 and 196–254 stabilising the Fc domain.

Critical Quality Attributes for Fc-Fusion Chain Integrity

The structural verification of dulaglutide requires monitoring of several critical quality attributes (CQAs) that collectively define the molecule’s identity, purity, and potency. These attributes reflect the unique challenges of Fc-fusion proteins, which are structurally more complex than monoclonal antibodies and require product-specific analytical methods beyond platform approaches.

Primary structure and sequence fidelity are verified through peptide mapping and mass spectrometry. Intact mass analysis of the homodimer provides a rapid identity check, while tryptic digestion followed by LC-MS/MS confirms the expected amino acid sequence, including the linker region and the engineered substitutions within the GLP-1 domain. The theoretical exact mass of the dulaglutide homodimer is 59,633 Da (molecular weight approximately 59,670 Da), with sequence coverage typically exceeding 96% using optimised digestion protocols.

Disulphide connectivity is a non-negotiable determinant of Fc-fusion chain integrity. The four inter-chain disulphide bonds (Cys55–Cys55′ and Cys58–Cys58′) must be correctly formed to maintain the covalent homodimer, while the intra-chain bonds within each Fc domain ensure proper folding. Analytical methods for disulphide mapping include non-reducing peptide mapping and mass spectrometry under controlled alkylation conditions.

Aggregation and fragmentation are monitored using size-exclusion chromatography (SEC-HPLC). SEC separates intact homodimers from higher-order aggregates and lower-molecular-weight fragments, providing a quantitative measure of structural purity. Aggregation is particularly relevant for Fc-fusion proteins because the Fc domain’s tendency to self-associate can compromise both safety and efficacy.

Linker integrity is a domain-specific concern. The glycine-serine linker must remain intact to preserve the spatial relationship between the GLP-1 and Fc domains. Cleavage within the linker would release a truncated GLP-1 fragment with altered pharmacology, while excessive linker flexibility could promote aggregation or misfolding.

Glycosylation is a critical attribute for Fc-fusion proteins, though dulaglutide’s IgG4 Fc domain is engineered to minimise glycosylation complexity relative to some fusion proteins . The Fc region of IgG4 typically carries an N-linked glycan at Asn297, and the glycosylation profile can influence Fc receptor binding, half-life, and immunogenicity. Multi-attribute method (MAM) workflows using LC-MS have been developed specifically for Fc-fusion protein characterisation, enabling simultaneous monitoring of glycosylation, deamidation, oxidation, and other post-translational modifications.

Analytical Strategies for Chain Verification

The complexity of Fc-fusion proteins demands a tiered analytical approach. A comprehensive verification strategy for dulaglutide includes the following components:

Intact mass analysis using LC-MS provides a rapid identity confirmation and detects gross structural deviations such as truncations or unexpected modifications. This method is particularly useful for lot release and comparability studies.

Peptide mapping with LC-MS/MS delivers amino acid sequence confirmation, disulphide mapping, and site-specific post-translational modification analysis. The MAM workflow developed for VEGFR-targeted Fc-fusion proteins demonstrates how optimised tryptic digestion (2 hours with >96% sequence coverage) can simultaneously quantify deamidation, oxidation, and glycosylation across the entire fusion protein.

Ion-exchange chromatography (IEX) resolves charge variants arising from deamidation, oxidation, or C-terminal lysine processing, providing insight into the chemical stability of the Fc-fusion chain.

Bioactivity assays using cell-based GLP-1 receptor activation confirm that the GLP-1 domains retain their functional conformation and that the Fc portion does not sterically hinder receptor engagement. Potency testing is essential because structural methods alone cannot guarantee that the fusion protein will elicit the intended pharmacological response.

Implications for Biosimilar Development

The structural verification standards for dulaglutide have particular relevance for biosimilar development. Demonstrating biosimilarity requires comprehensive structural characterisation to establish that the proposed product is highly similar to the reference product despite minor differences in post-translational modifications. The Fc-fusion architecture introduces additional complexity relative to standard monoclonal antibodies, as the linker region, disulphide connectivity, and domain-domain interactions must all be verified. Analytical strategies for Fc-fusion biosimilars must therefore extend beyond conventional mAb characterisation platforms to include product-specific methods for linker integrity and GLP-1 domain conformation.

Conclusion

Dulaglutide’s therapeutic success depends on the precise assembly and maintenance of its Fc-fusion chain architecture. Verification standards for this molecule encompass a multi-attribute analytical framework that confirms primary structure, disulphide connectivity, aggregation state, linker integrity, and post-translational modifications. As Fc-fusion proteins continue to represent a growing class of biopharmaceuticals, the analytical methodologies developed for dulaglutide provide a template for ensuring structural integrity across this complex and therapeutically important modality.